Eli Lilly 2026년 5월 21일 Lilly’s triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile - Fierce Biotech
Eli Lilly 2026년 5월 21일 Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial | Eli Lilly and Company - investor.lilly.com
Eli Lilly 2026년 5월 21일 Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling - BioSpace
Eli Lilly 2026년 5월 21일 Eli Lilly maintains M&A streak with $202m Engage Bio buyout - Pharmaceutical Technology
Eli Lilly 2026년 5월 20일 Elil Lilly buys a Bay Area Y Combinator alum for up to $202M - The Business Journals
Eli Lilly 2026년 5월 20일 Collaborative Drug Discovery Inks Deal with Eli Lilly to Accelerate Biotech Innovation - Genetic Engineering and Biotechnology News
Eli Lilly 2026년 5월 20일 Lilly pens $202M deal for preclinical DNA delivery biotech Engage as M&A streak continues - Fierce Biotech
Eli Lilly 2026년 5월 19일 Supreme Court Ruling Puts Eli Lilly Medicaid Compliance And Investor Risks In Focus - simplywall.st
Eli Lilly 2026년 5월 18일 Eli Lilly teams up with Caitlin Clark to bounce sports courts into Indianapolis neighborhoods - Fierce Pharma
Eli Lilly 2026년 5월 18일 Vincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators - Fierce Biotech
Eli Lilly 2026년 5월 18일 Eli Lilly and Company Enters $2.3 Billion Agreement to Acquire Ajax Therapeutics - The Healthcare Technology Report.
Eli Lilly 2026년 5월 18일 Vincetage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators - Fierce Biotech
Eli Lilly 2026년 5월 17일 Could Eli Lilly's Next Weight Loss Drug Waylay Wegovy -- and Even Zap Zepbound? - The Motley Fool